Phase III Study of S-877503 in Adult Patients with Attention-deficit/Hyperactivity Disorder
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Guanfacine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shionogi; Shire
- 11 May 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2016 Status changed from planning to recruiting.
- 17 Dec 2015 New trial record